Optimizing Tissue-free ctDNA Evaluations with QCT Technology: Enhancing Sensitivity for Therapy Selection & Enabling Quantitative Therapy Response Monitoring
Time: 12:00 pm
day: Day Two Track B (AM)
Details:
- Employing our patented QCT technology to achieve single molecule resolution
- Enhanced limit of detection augments sensitivity in low-VAF setting to improve detection of clinically actionable alterations
- Precise therapy Response quantification and clonal profiling through a personalized methylation-based approach
